Paper30901302
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A and 30 others. J Clin Oncol, 2019. Cited by 516 papers, by iCite.
Cite this record
ConductScience Library. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. Papers, record 30901302. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30901302
- Disease
- diffuse large B-cell lymphoma301 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Connected records3
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Adenine | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Cyclophosphamide | |
| Double-Blind Method | |
| Doxorubicin | |
| Female | |
| Humans | |
| Kaplan-Meier Estimate | |
| Male | |
| Middle Aged | |
| Piperidines | |
| Placebos | |
| Prednisone | |
| Progression-Free Survival | |
| Pyrazoles | |
| Pyrimidines | |
| Rituximab | |
| Survival Rate | |
| Vincristine | |
| Young Adult |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| ZIABC011354 | NIH | NIH RePORTER |
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT06251180 | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma | Results | ClinicalTrials.gov |
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 30945958 | De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma. | https://conductscience.org/library/papers/30945958 | PubMed |
| Comment in | 31390273 | Reply to M. Skelin et al. | https://conductscience.org/library/papers/31390273 | PubMed |
| Comment in | 31390275 | Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL? | https://conductscience.org/library/papers/31390275 | PubMed |
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10676951 | Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. | Nature | 2000 | https://conductscience.org/library/papers/10676951 | PubMed |
| 2 | 11160144 | Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. | J Clin Invest | 2001 | https://conductscience.org/library/papers/11160144 | PubMed |
| 3 | 14504078 | Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. | Blood | 2004 | https://conductscience.org/library/papers/14504078 | PubMed |
| 4 | 17242396 | Revised response criteria for malignant lymphoma. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17242396 | PubMed |
| 5 | 17266164 | A method for testing a prespecified subgroup in clinical trials. | Stat Med | 2007 | https://conductscience.org/library/papers/17266164 | PubMed |
| 6 | 23339126 | Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23339126 | PubMed |
| 7 | 23454758 | Causes, consequences, and reversal of immune system aging. | J Clin Invest | 2013 | https://conductscience.org/library/papers/23454758 | PubMed |
| 8 | 24398326 | Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. | Blood | 2014 | https://conductscience.org/library/papers/24398326 | PubMed |
| 9 | 25042202 | Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/25042202 | PubMed |
| 10 | 25342313 | Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. | Oncologist | 2014 | https://conductscience.org/library/papers/25342313 | PubMed |
| 11 | 25488930 | Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. | Drug Metab Dispos | 2015 | https://conductscience.org/library/papers/25488930 | PubMed |
| 12 | 25884669 | A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival. | BMC Cancer | 2015 | https://conductscience.org/library/papers/25884669 | PubMed |
| 13 | 26193343 | Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. | Nat Med | 2015 | https://conductscience.org/library/papers/26193343 | PubMed |
| 14 | 26314773 | Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2015 | https://conductscience.org/library/papers/26314773 | PubMed |
| 15 | 27089170 | ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. | Future Oncol | 2016 | https://conductscience.org/library/papers/27089170 | PubMed |
| 16 | 28426350 | Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28426350 | PubMed |
| 17 | 28751558 | Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. | Haematologica | 2017 | https://conductscience.org/library/papers/28751558 | PubMed |
| 18 | 28796588 | Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28796588 | PubMed |
| 19 | 29641966 | Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29641966 | PubMed |
| 20 | 29672223 | Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29672223 | PubMed |
Cited by340
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 516 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42972012 | The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma. | Leukemia | 2026 | https://conductscience.org/library/papers/42972012 | PubMed |
| 42827714 | Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42827714 | PubMed |
| 42636799 | Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42636799 | PubMed |
| 42608144 | Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study. | Br J Haematol | 2026 | https://conductscience.org/library/papers/42608144 | PubMed |
| 42571242 | Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/42571242 | PubMed |
| 42500562 | Transcriptomic Study of Diffuse Large B-Cell Lymphoma Associated with HIV Infection: Identification of Novel Molecular Subtypes. | Oncol Res | 2026 | https://conductscience.org/library/papers/42500562 | PubMed |
| 42487683 | Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes. | Annu Rev Cancer Biol | 2026 | https://conductscience.org/library/papers/42487683 | PubMed |
| 42439665 | Diffuse Large B-Cell Lymphoma: From Molecular Stratification to Precision Immunotherapy. | Cells | 2026 | https://conductscience.org/library/papers/42439665 | PubMed |
| 42426809 | R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study. | BMC Med | 2026 | https://conductscience.org/library/papers/42426809 | PubMed |
| 42403594 | A Critical Review of PET/CT Assessment After CAR-T Cell Therapy in Large B-Cell Lymphoma, Limitations of Current Criteria, Emerging Biomarkers, and a Framework for Standardised Evaluation. | J Multidiscip Healthc | 2026 | https://conductscience.org/library/papers/42403594 | PubMed |
| 42386710 | Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/42386710 | PubMed |
| 42377894 | A case study of proteomics-guided personalized targeted therapy. | Sci China Life Sci | 2026 | https://conductscience.org/library/papers/42377894 | PubMed |
| 42369727 | Management of diffuse large B‑cell lymphoma in older adults: current strategies and emerging directions. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/42369727 | PubMed |
| 42362499 | Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/42362499 | PubMed |
| 42295240 | Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. | Mol Cancer Ther | 2026 | https://conductscience.org/library/papers/42295240 | PubMed |
| 42286378 | Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma. | Int J Clin Oncol | 2026 | https://conductscience.org/library/papers/42286378 | PubMed |
| 42175874 | Response to: "Refining Combined-Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma". | Am J Hematol | 2026 | https://conductscience.org/library/papers/42175874 | PubMed |
| 42172280 | Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study. | PLoS One | 2026 | https://conductscience.org/library/papers/42172280 | PubMed |
| 42151585 | Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation. | Ann Hematol | 2026 | https://conductscience.org/library/papers/42151585 | PubMed |
| 42074785 | Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results. | J Clin Med | 2026 | https://conductscience.org/library/papers/42074785 | PubMed |
Drugs7
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL1200796 | ChEMBL |
| RITUXIMAB | CHEMBL1201576 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL1201576 | ChEMBL |
| IBRUTINIB | CHEMBL1873475 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1873475 | ChEMBL |
| ROCBRUTINIB | CHEMBL5314539 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL5314539 | ChEMBL |
| DOXORUBICIN | CHEMBL53463 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL53463 | ChEMBL |
| PREDNISONE | CHEMBL635 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL635 | ChEMBL |
| VINCRISTINE | CHEMBL90555 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL90555 | ChEMBL |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| EudraCT | 2013-000959-40 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Genes
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30901302
GET https://conductscience.org/api/papers/v1/30901302/authors?page=2